Spotlight Growth
No Result
View All Result
Thursday, February 2, 2023
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
No Result
View All Result
No Result
View All Result
Home Bio/Med/Pharma

Prometheus Biosciences (NASDAQ: RXDX) Reports PRA023 Candidate Achieved Positive Results in Both its ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Clinical Trials

by admin
December 7, 2022
in Bio/Med/Pharma
0
Prometheus Biosciences NASDAQ RXDX PRA023 Phase 2 Clinical Trial Results Spotlight Growth

Prometheus Biosciences NASDAQ RXDX PRA023 Phase 2 Clinical Trial Results Spotlight Growth

Prometheus Biosciences, Inc. (NASDAQ: RXDX) is engaged as a clinical-stage biotechnology company, which is focused on the research, development and commercialization of novel therapeutics for the treatment of immune-mediated diseases. Shares of the biotech company are skyrocketing 175% through early trading on Wednesday, December 7, 2022. Over the past three months, Prometheus Biosciences has seen average daily volume of 597,160 shares. However, volume of 6.14 million shares or dollar volume of around $610.56 million, has already exchanged hands through early trading.

Shares of Prometheus Biosciences are surging after the company announced positive results from its PRA023 drug candidate in recent clinical trials. PRA023 is a IgG1 humanized monoclonal antibody that has shown the ability to block tumor necrosis factor (TNF)-like ligand 1A (TL1A). This could help provide potentially-substantial improvements for patients suffering from moderate-to-severe irritable bowel disease (IBD).

PRA023 recently underwent a successful ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a clinical studies, which puts the drug candidate on the path to becoming both the first-in-class and the best-in-class treatment for Anti-TL1a mAb.

The Phase 2 ARTEMIS-UC trial was a 12-week, double-blind, placebo-controlled, randomized study that sought to test the efficacy and safety of PRA023 in patients suffering from moderate-to-severe active UC and have no responded to traditional treatments. The results showed 26.5% of patients being treated with PRA023 reached the primary endpoint of clinical remission, compared to only 1.5% in the placebo group. Furthermore, 36.8% of PRA023 patients achieved their secondary endpoint of endoscopic improvements, compared to only 6% in the placebo group.

During the Phase 2a APOLLO-CD trial, patients underwent a 12-week open-label study that enrolled 55 patients with moderate-to-severe active CD and have not responded to traditional treatments. The results showed 26% of patients on PRA023 saw a meaningful endoscopic response, compared to only 12% in the placebo group. In addition, 49.1% of patients taking the drug candidate achieved clinical remission compared to only 16% in the placebo group.

“PRA023 has clearly demonstrated clinical proof-of-concept in CD and remarkable efficacy for the treatment of UC,” added Allison Luo, MD, Chief Medical Officer. “We are grateful to all of our investigators and patients for their participation and look forward to further evaluating PRA023 in Phase 3 studies with the goal of bringing this promising candidate to the market.”

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

Tags: biopharmaceuticalsbiotechCD treatmentclinical trialscommon stockCrohn's diseaseday tradingdow jones todayemerging growthFDAFDA newsIBDIBD treatmentinvestinginvesting newsinvestmentmedicalmicrocap stocksNASDAQnewspharmaceuticalsPhase 2 clinical trialsPrometheus Biosciencespublic companyRXDXRXDX stocksmall cap companiessmall cap stockssmall capsSpotlight GrowthSpotlight Growth Stocksstock marketstock newsstocksstocks to watchtradingtreatmentUC treatmentwebull wallstreetbets
  • Trending
  • Comments
  • Latest
Asure Software NASDAQ ASUR Human Capital Management HCM Industry Spotlight Growth

Asure Software (NASDAQ: ASUR) is Expanding to Meet the Rising Demand for Human Capital Management Software

September 27, 2022
OLB Group NASDAQ OLB Cuentas NASDAQ CUEN Partnership Fintech Spotlight Growth

OLB Group (NASDAQ: OLB) and Cuentas (NASDAQ: CUEN) Team Up to Bring Fintech Solutions to Over 32,000 Bodegas Across the United States

October 6, 2022
Siyata Mobile NASDAQ SYTA SYTAW SD7 VK7 Purchase Orders Spotlight Growth

New Purchase Orders for SD7 Rugged Device, VK7, and Other Accessories Boost Siyata Mobile’s Outlook (NASDAQ: SYTA)

December 14, 2021
Telcoin TEL Crypto Spotlight Growth

Telcoin (TEL) Quietly Leads a Crypto Remittance Revolution

June 15, 2021
Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

0
Safe-T SFET NASDAQ UN Presentation

Safe-T (NASDAQ: SFET) Has Been Selected to Present at the United Nations’ Office of Information and Communications Technology Event

0
Safe-T Group SFET Q4 FY 2020 Financial Results

Safe-T Group (NASDAQ: SFET) Reports Fourth Quarter and Full Year 2020 Financial Results

0
Safe-T Group NASDAQ SFET FY 2020 Prelim

Safe-T Group Ltd. (NASDAQ: SFET) Estimates Record-High Annual Revenues of Approximately $4.9 Million Representing ~50% Growth YoY 2020

0
Elys Game Technology Corp NASDAQ ELYS Completes Acquisition of Engage IT Services Spotlight Growth

Elys Game Technology Corp (NASDAQ: ELYS) Completes Acquisition of Engage IT Services, a Software Engineering and IT Development Company

February 2, 2023
Tenax Therapeutics NASDAQ TENX US Patent Levosimendan PH-HFpEF Spotlight Growth

Tenax Therapeutics (NASDAQ: TENX) Granted U.S. Patent for IV Levosimendan for Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

February 2, 2023
Versus Systems NASDAQ VS Resolve Debt Partner AI Gamification Consumer Debt Spotlight Growth

Versus Systems (NASDAQ: VS) and Resolve Debt Partner to Integrated Generative AI and Gamification to Customer Payments and Credit Markets

February 1, 2023
Finding the Most Accurate Technical Analysis Indicator Spotlight Growth

Finding the Most Accurate Technical Analysis Indicator

January 31, 2023
ADVERTISEMENT

Recent News

Elys Game Technology Corp NASDAQ ELYS Completes Acquisition of Engage IT Services Spotlight Growth

Elys Game Technology Corp (NASDAQ: ELYS) Completes Acquisition of Engage IT Services, a Software Engineering and IT Development Company

February 2, 2023
Tenax Therapeutics NASDAQ TENX US Patent Levosimendan PH-HFpEF Spotlight Growth

Tenax Therapeutics (NASDAQ: TENX) Granted U.S. Patent for IV Levosimendan for Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

February 2, 2023

Categories

  • Bio/Med/Pharma
  • Cannabis
  • Commodities
  • Consumer Goods
  • Crowdfunding
  • Crypto Cheat Sheets
  • Cryptocurrency
  • Earnings
  • Education
  • Entertainment
  • Financials
  • Market News
  • Opinion
  • Politics
  • Real Estate
  • Split Watch
  • Sponsored
  • Store
  • Technology
  • Uncategorized
  • Venture Capital/Private Equity (VC/PE)

Site Navigation

  • Disclosures
  • Terms Of Service
  • Privacy Policy
  • Contact Us

Copyright © 2017-2022 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

No Result
View All Result
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener

Copyright © 2017-2022 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

Newsletter Signup

Subscribe to our weekly newsletter below and never miss the latest small/micro-cap analysis and investment news from Spotlight Growth.

Enter your email address

Thanks, I’m not interested